About the Event

Learn about the processes, protocols, planning steps, key questions, and indicators of success alongside a discussion of the challenges involved in moving through translation, clinical planning, scale-up and manufacturing at lightning speed.

The University of Queensland entered into a partnering agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) in January 2019, to develop a “molecular clamp” vaccine platform, a transformative technology that enables targeted and rapid vaccine production against multiple viral pathogens. In January 2020, that partnership was expanded to develop that platform in order to produce a vaccine candidate against COVID-19.

In order to rapidly progress the vaccine candidate into the clinic and beyond UQ has been joined by CSL as full development partner and ‘trusted manufacturer’.

First in human trials are planned to take place in July 2020 and planning is well underway for the scale-up manufacturing at CSL Broadmeadows recombinant manufacturing facility to support Phase 2 and 3 trials, then provision to Australia and globally.

---